Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

Sponsor
Poitiers University Hospital
Study ID
NCT01872546
Phase
PHASE2
Status
Completed

Conditions

  • Chronic Plaque Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab Every Week — DRUG
    Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.

Study Details

The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Key Dates

Start date
Jan 31, 2013
Status verified
Oct 2016
Primary completion
Apr 30, 2013
Completion
Sep 30, 2013

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab
    Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.

Primary Outcome Measure

Area and Severity Index (PASI) [ Time Frame: 4 weeks ]

Related coverage on Hipa.ai